Daniel de Boer, ProQR CEO
August 1, 2023 03:36 PM EDT
Deals
Pharma

Pro­QR finds eye dis­ease part­ner in Eu­rope, hands off two late-stage can­di­dates

Paul Schloesser

Associate Editor

Pro­QR has inked a deal with French com­pa­ny Lab­o­ra­toires Théa and trans­fer­ring two late-stage can­di­dates to the com­pa­ny in a deal worth up to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times